Holen Sie sich die Stockscreener-App
71.61
2.50%
1.725
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Astrazeneca PLC Aktie (AZN) Neueste Nachrichten
AstraZeneca (NASDAQ:AZN) PLC Stock Sees Institutional Growth on Nasdaq Composite - Kalkine Media
AstraZeneca and GSK fall after Trump renews pharma tariff threat - Proactive Investors
FTSE 100 Live: Stocks drop and oil spikes as Iran 'will not surrender', AstraZeneca falls on tariff threat - Proactive Investors
FTSE 100 Live: Stocks drop into the red, AstraZeneca and GSK fall on Trump tariff threat - Proactive Investors
AstraZeneca, GSK shares down after Trump threatens drug import tariffs By Investing.com - Investing.com Nigeria
FTSE 100 Live: Stocks edge higher as UK inflation eases, AstraZeneca and GSK fall - Proactive Investors
FTSE 100 Live: Stocks open higher as UK inflation eases, AstraZeneca and GSK fall - Proactive Investors
Astrazeneca makes $5.3B drug R&D pact with CSPC - BioWorld MedTech
AstraZeneca (AZN) Faces Potential Changes in Drug Advertising Ru - GuruFocus
Levi & Korsinsky Reminds AstraZeneca PLC Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025AZN - ACCESS Newswire
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer - Insider Monkey
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
Sector Update: Health Care Stocks Slide Late Afternoon - MarketScreener
AstraZeneca Inks Up To $5.3B AI Drug Deal With Chinese Firm - Law360
FIVE AT FIVE: FTSE 100 unsettled by Israel strike; AstraZeneca strikes $3.6bn Chinese AI deal - Proactive financial news
AstraZeneca and CSPC partner on AI drug research By Investing.com - Investing.com Nigeria
AstraZeneca and CSPC partner on AI drug research - Investing.com
AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal - Pharmaceutical Technology
AstraZeneca, CSPC Pharmaceuticals Enter Research Agreement - marketscreener.com
AstraZeneca signs research agreement with China's CSPC (AZN) - Seeking Alpha
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans - BioPharma Dive
AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance - insights.citeline.com
AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 BillionAstraZeneca (NASDAQ:AZN) - Benzinga
AstraZeneca, Chinese bio firm sign $5.2B drug deal - breakingthenews.net
AstraZeneca signs $5.2bn deal to develop drugs for chronic disease with Chinese biotech - Financial Times
AstraZeneca Signs Nearly $5.3 Bln AI-enabled Research Deal With China's CSPC Pharma - Nasdaq
AstraZeneca (AZN) Enters Collaboration with CSPC for Novel Thera - GuruFocus
AstraZeneca: R&D agreement with CSPC Pharmaceuticals Group - MarketScreener
AstraZeneca bets big on AI and China with $3.6bn CSPC collaboration - Proactive financial news
AstraZeneca Enters Strategic Collaboration with CSPC Pharmaceuticals Group Limited - marketscreener.com
AstraZeneca, CSPC Ink Strategic Research Collaboration for AI-Driven Drug Discovery - marketscreener.com
The Zacks Analyst Blog Highlights Microsoft, AstraZeneca and BlackRock, Taylor Devices and Geospace Technologies - TradingView
AstraZeneca partners with CSPC in deal worth up to $5.33 billion - Investing.com Nigeria
AstraZeneca forms $5.3 billion AI drug discovery deal with CSPC - Investing.com
AstraZeneca signs AI research deal with China's CSPC for chronic diseases - MarketScreener
AstraZeneca agrees to research deal worth up to $5.22 billion with CSPC - Yahoo Finance
Astrazeneca Enters Collaboration Worth Up To $5.22 Bln With CSPC Pharmaceuticals - marketscreener.com
Top Stock Reports for Microsoft, AstraZeneca & BlackRock - Yahoo Finance
Chancery Tags AstraZeneca Unit For $180M 'Expectation' Loss - Law360
Leading bank sees AstraZeneca upside seen in hypertension drug, tempers lung cancer hopes - Proactive financial news
AstraZeneca CFO Donates Shares to Charity - TipRanks
AstraZeneca CFO donates shares to charity - Investing.com
AstraZeneca CFO donates shares to charity By Investing.com - Investing.com UK
REGAstraZeneca PLCDirector/PDMR Shareholding - TradingView
AstraZeneca (AZN): Vaccine Advisory Panel Reshuffled, Impact on Pharma Stocks | AZN Stock News - GuruFocus
UBS bullish on AstraZeneca’s baxdrostat, cautious on AVANZAR By Investing.com - Investing.com Nigeria
At a bargain-basement valuation now, is AstraZeneca’s share price impossible for me to ignore? - Yahoo
AstraZeneca (AZN) Watches CDC Vaccine Policy Developments | AZN Stock News - GuruFocus
AstraZeneca Unit Owes $180 Million-Plus in Syntimmune Case (1) - Bloomberg Law News
AstraZeneca, Lilly & J&J: Strategic Moves Powering SGLT‐2 - openPR.com
Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
AstraZeneca (AZN) Faces Competitive Pressure in Blood Pressure M - GuruFocus
AstraZeneca (LSE:AZN) Partners In Quantum Leap For Drug Development Efficiency - Yahoo Finance
AstraZeneca PLC (AZN) to Restructure U.S. Vaccine Advisory Committee Amid Trust Issues | AZN Stock - paginasiete.bo
AstraZeneca (AZN) to Restructure U.S. Vaccine Advisory Committee Amid Trust Issues | AZN Stock News - GuruFocus
MORNING BID AMERICAS-White smoke or London fog? - marketscreener.com
AstraZeneca (AZN) Among Key Players in Pharmaceutical Sector | A - GuruFocus
AstraZeneca PLC Being Investigated on Behalf of AstraZeneca PLC Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
AstraZeneca (AZN) Faces Challenges Amid Public Trust Crisis in Vaccines | AZN Stock News - GuruFocus
Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season - AOL.com
AstraZeneca Pharma India names Praveen Rao Akkinepally as new MD, succeeding Dr Sanjeev Panchal - Medical Dialogues
Quantum Computing Breakthrough: IonQ Slashes Drug Development Time From Months to Days - Stock Titan
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):